Lonza unveils significant investment plan in China
Swiss-based Lonza Group is to expand significantly its activities in Nansha Guangzhou, China. The strategic investment will amount to US$200m over the next few years and will enhance Lonza's existing production operations in Guangzhou.
Swiss-based Lonza Group is to expand significantly its activities in Nansha Guangzhou, China. The strategic investment will amount to US$200m over the next few years and will enhance Lonza's existing production operations in Guangzhou.
The investment will be phased over a three to five year period and includes the building of a multi-purpose API (active pharmaceutical ingredients) and ISO-regulated intermediate plant complex which delivers large scale and pilot scale production capabilities.
"This project will mark another important milestone in Lonza's long-term strategic plan. It is a key element in achieving the targeted growth for Lonza," said Stefan Borgas, ceo of Lonza. "Since 1995, Lonza Group has selected Guangzhou City to be its investment front in China. We firmly believe that this region offers cutting-edge technology platforms, manufacturing excellence, and a competitive cost environment which complements Lonza's other international sites."
Lonza's investment will build upon the current foundation existing in China, and will combine international knowledge with local expertise. This will deliver a broader range of capacities, products and services, the company says.
The Group recently celebrated the tenth anniversary of thriving operations of Lonza Guangzhou Ltd, the inauguration of Lonza Guangzhou Nansha Ltd and the completion of the new Nansha r&d complex.
Lonza currently produces a significant share of the global market of Niacinamide (Vitamin B3) in its two operations in Guangzhou City. The r&d centre, located in the Nansha Development Zone, participates in developmental activities for intermediates and active ingredients for the pharmaceutical and fine chemical industries worldwide.